HSR25-152: Incidence of Hematologic Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials

Authors

• R. Srinvasmurthy
• H. Aboaid
• A. Hussain
• R. Hattin
• S. Schauer
• T. Schlesinger
• R. Twells
• K. Aharonian
• R. Parto
• R. Rahmani
• C. Lambert-Swainston
• D. T. Jones
• Kyaw Z. Thein, Touro University NevadaFollow

Roles

Author

Document Type

Article

Publication Date

1-1-2025

Publication Title

Journal of the National Comprehensive Cancer Network

DOI

10.6004/jnccn.2024.7316

Recommended Citation

Srinvasmurthy, R., Aboaid, H., Hussain, A., Hattin, R., Schauer, S., Schlesinger, T., Twells, R., Aharonian, K., Parto, R., Rahmani, R., Lambert-Swainston, C., Jones, D. T., & Thein, K. Z. (2025). HSR25-152: Incidence of Hematologic Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials. Journal of the National Comprehensive Cancer Network, 23 (3.5), Article HSR25-152. https://doi.org/10.6004/jnccn.2024.7316